BETA

5 Amendments of Massimiliano SALINI related to 2020/2071(INI)

Amendment 14 #
Draft opinion
Paragraph 2
2. Recognises that the EU depends on a narrow set of countries for a large proportion of its imports of active pharmaceutical ingredients and chemical raw materials; stresses that this over- reliance can pose a risk when limitations in production capacity, excess demand or protectionist measures, including restrictions on export inside and outside the EU, threaten the proper functioning of global supply chains and potentially undermine the availability of medicines in the EU; calls on the Commission to present a long-term strategy focused on ensuring the EU’s open strategic autonomy in health, also on the basis of all the factors that adversely affect the availability of drugs;
2020/05/18
Committee: INTA
Amendment 23 #
Draft opinion
Paragraph 2 a (new)
2 a. Insists that the measures proposed in the Commission's upcoming Pharmaceutical Strategy should ensure Europe's central role as an "innovator and world leader", as underlined in President von der Leyen's mission letter to Commissioner Stella Kyriakides, recognising that the start of any EU policy aimed at bringing the production of medicines and active ingredients back into Europe starts by strengthening research;
2020/05/18
Committee: INTA
Amendment 32 #
Draft opinion
Paragraph 3
3. Emphasises that the EU is a leading global exporter of pharmaceutical products; notes that the protection and enforcement of IP rights in free trade agreements (FTAs) and at the WTO is crucial to the development of new medicines and treatments and EU's competitive position in innovation; underlines that the flexibilities provided in the TRIPS agreement can be used to address potential supply shortages in exceptional circumstances;
2020/05/18
Committee: INTA
Amendment 40 #
Draft opinion
Paragraph 4
4. Emphasises that a broad network of FTAs that take into account components of intellectual property, together with a functioning multilateral trading system constitute the best way of guaranteeing that multiple sources of manufacturing for essential medicines are available and regulatory standards converge globally in order to maintain in Europe and the world a strong innovation framework able to withstand future health crises;
2020/05/18
Committee: INTA
Amendment 48 #
Draft opinion
Paragraph 5
5. Strongly encourages all countries to join the WTO’s Pharmaceutical Tariff Elimination Agreement; calls for its scope to be extended to all pharmaceutical and medicinal products; stresses that medical products and pharmaceuticals, including in their intermediate forms, should be exempted from retaliation in trade disputes;
2020/05/18
Committee: INTA